A

Alnylam Pharmaceuticals

Develops RNAi-based therapies for genetic diseases

Director, Biostatistics

Quantitative Biology & BiostatisticsConfirmed live in the last 24 hours
Full-timeCambridge, MA, USA$212.5k - $287.5kIn-person

About the Job

Requirements

  • A Ph.D. in Statistics or Biostatistics, or equivalent, is preferred, together with at least 8–10 years of pharmaceutical statistics experience.
  • Experience designing and supporting late-phase (Phase 2/3) clinical studies.
  • Experience conducting clinical trial simulations to evaluate design options, operating characteristics, and decision criteria.
  • Experience with Bayesian and adaptive clinical trial design.
  • Experience leading or supporting NDA and MAA submissions.
  • Proficiency in SAS and R programming languages.
  • Experience representing sponsors in meetings with the U.S. FDA and international regulatory authorities.
  • Excellent written and oral communication and presentation skills.
  • Interest in and basic understanding of biology and biological processes, including RNAi.

Responsibilities

  • Provide leadership and guidance for large and/or complex late-phase clinical development programs.
  • Contribute to strategic thinking and Clinical Development Plan development.
  • Lead large and/or complex late-phase clinical development programs.
  • Promote teamwork, quality, and innovation through collaboration with program teams and foster a productive work environment.
  • Collaborate with Clinical Development, Regulatory, and Clinical Operations Expertise Areas to design innovative clinical trials.
  • Author statistical sections of clinical trial protocols and statistical analysis plans.
  • Review and approve stratification and randomization schemas.
  • Collaborate with Data Management, Clinical Development, and Clinical Operations on eCRF design.
  • Provide statistical guidance on the conduct of ongoing trials.
  • Collaborate with Statistical Programmers on trial data summaries and analyses, and write ADaM and ad hoc analysis specifications.
  • Interpret and communicate statistical analysis results from clinical trial data in support of regulatory submissions and manuscripts.
  • Contribute to clinical study reports and other regulatory documents, including DSURs and briefing documents.
  • Lead biostatistics support for worldwide regulatory submissions.
  • Represent Alnylam in meetings with regulators, Key Opinion Leaders, partners, and other stakeholders.
  • Contribute to scientific articles summarizing data collected in Alnylam trials.
  • Consult with Research, Preclinical, Clinical Pharmacology, Medical Affairs, and Commercial colleagues on statistical questions.
  • Manage timelines across the clinical development program.

About the Company

Alnylam Pharmaceuticals

Develops RNAi-based therapies for genetic diseases

Alnylam Pharmaceuticals develops RNA interference (RNAi) therapeutics to silence disease-causing genes, aiming to treat rare genetic disorders. Its products work by using RNA molecules that block gene expression, reducing the impact of specific genetic diseases. The company differentiates itself by concentrating on RNAi-based drugs for rare diseases and by building a pipeline through large clinical programs and strategic partnerships, such as commercialization deals in the Gulf States and collaborations with investors. Revenue comes from approved drug sales, licensing agreements, strategic collaborations, and related services like genetic testing and counseling. The company’s goal is to advance and commercialize RNAi therapies to improve outcomes for patients with genetic disorders, expanding its portfolio through partnerships and investments.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Cambridge, MA
Founded
2002

Recently Posted Jobs

Explore more opportunities at Alnylam Pharmaceuticals

See more jobs